| 32nd week of 2018 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20180221275 | ORAL PRODUCT | 2018-08-09 |
| 20180221276 | WELLNESS DRINK AND METHOD OF MANUFACTURE | 2018-08-09 |
| 20180221277 | Transdermal Drug Delivery Using Amphiphilic Dendron-Coil Micelles | 2018-08-09 |
| 20180221278 | PRSUSTAINED RELEASE OPTHALMIC FORMUATION AND METHODS FOR USING THE SAME | 2018-08-09 |
| 20180221279 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | 2018-08-09 |
| 20180221280 | HEAT-STABLE DRY POWDER PHARMACEUTICAL COMPOSITIONS AND METHODS | 2018-08-09 |
| 20180221281 | Sol-Gel Phase-Reversible Hydrogel Templates and Uses Thereof | 2018-08-09 |
| 20180221282 | METHODS FOR MAKING PHARMACEUTICAL SOLID DOSAGE FORMS OF SPRAY-DRIED DISPERSIONS | 2018-08-09 |
| 20180221283 | NANOSUSPENSION CONTAINING PARTICLES AND EXTRACT OF NATURAL MATERIALS | 2018-08-09 |
| 20180221284 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | 2018-08-09 |
| 20180221285 | ORAL FORMULATIONS OF DEFERASIROX | 2018-08-09 |
| 20180221286 | TARGETED GASTROINTESTINAL TRACT DELIVERY OF PROBIOTIC ORGANISMS AND/OR THERAPEUTIC AGENTS | 2018-08-09 |
| 20180221287 | METHODS FOR DELIVERING INSULIN PREPARATIONS INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | 2018-08-09 |
| 20180221288 | ENTERIC CAPSULE | 2018-08-09 |
| 20180221289 | PHOSPHOLIPID-CHOLESTERYL ESTER NANOFORMULATIONS AND RELATED METHODS | 2018-08-09 |
| 20180221290 | EXTENDED RELEASE SUSPENSION COMPOSITIONS | 2018-08-09 |
| 20180221291 | Process for forming Janus particles and Application Thereof | 2018-08-09 |
| 20180221292 | Janus particles and Application Thereof | 2018-08-09 |
| 20180221293 | MUCUS PENETRATING PARTICLES WITH HIGH MOLECULAR WEIGHT AND DENSE COATINGS | 2018-08-09 |
| 20180221294 | SOLID NANOPARTICLE WITH INORGANIC COATING | 2018-08-09 |
| 20180221295 | PHARMACEUTICAL COMPOSITION COMPRISING ELECTROHYDRODYNAMICALLY OBTAINED FIBRES, THE COMPOSITION HAVING IMPROVED RESIDENCE TIME ON THE APPLICATION SITE | 2018-08-09 |
| 20180221296 | INTRASITE ADMINISTRATION AND DOSING METHODS AND PHARMACEUTICALS FOR USE THEREIN | 2018-08-09 |
| 20180221297 | System and Method for Improving Adhesion of Transdermal Delivery Devices | 2018-08-09 |
| 20180221298 | TRANSDERMAL DELIVERY SYSTEM | 2018-08-09 |
| 20180221299 | TRANSDERMAL DELIVERY SYSTEM | 2018-08-09 |
| 20180221300 | Transdermal Delivery System Including an Interface Mediator | 2018-08-09 |
| 20180221301 | TRANSDERMAL SYSTEMS CONTAINING MULTILAYER ADHESIVE MATRICES TO MODIFY DRUG DELIVERY | 2018-08-09 |
| 20180221302 | ADJUSTING PARTICLE SIZE IN FLUOROCARBON NANOEMULSIONS | 2018-08-09 |
| 20180221303 | PERITONEAL THERAPEUTIC FLUID | 2018-08-09 |
| 20180221304 | CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF MAST CELL-ASSOCIATED OR BASOPHIL-MEDIATED INFLAMMATORY DISORDERS | 2018-08-09 |
| 20180221305 | ANTIMICROBIALS AND METHODS OF USE THEREOF FOR WOUND HEALING | 2018-08-09 |
| 20180221306 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | 2018-08-09 |
| 20180221307 | TAMPER RESISTANT DOSAGE FORM WITH BIMODAL RELEASE PROFILE MANUFACTURED BY CO-EXTRUSION | 2018-08-09 |
| 20180221308 | PROLONGED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)PHENOL | 2018-08-09 |
| 20180221309 | TREATMENT AND PREVENTION OF FUNGAL INFECTIONS | 2018-08-09 |
| 20180221310 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT | 2018-08-09 |
| 20180221311 | MATERIALS AND METHODS FOR CONTROLLING INFECTIONS | 2018-08-09 |
| 20180221312 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | 2018-08-09 |
| 20180221313 | USE OF HYDROXYCARBAMIDE FOR PREVENTING RETINAL NONPERFUSION | 2018-08-09 |
| 20180221314 | ORAL LIQUID COMPOSITIONS OF GUANFACINE | 2018-08-09 |
| 20180221315 | COMBINATION THERAPY USING ACAMPROSATE AND D-CYCLOSERINE | 2018-08-09 |
| 20180221316 | METHODS AND MATERIALS FOR REDUCING DAMAGE TO TRANSPLANTED TISSUE | 2018-08-09 |
| 20180221317 | COMPOSITION FOR THE TREATMENT OF SUPERFICIAL LESIONS | 2018-08-09 |
| 20180221318 | Compositions and Methods for Treating Skin Conditions Using Light and Polycarboxylic Acids | 2018-08-09 |
| 20180221319 | METHODS OF TREATING SEIZURE DISORDERS AND PRADER-WILLI SYNDROME | 2018-08-09 |
| 20180221320 | TREATMENT AND PREVENTION OF MUSCLE LOSS USING L-ORNITHINE IN COMBINATION WITH AT LEAST ONE OF PHENYLACETATE AND PHENYLBUTYRATE | 2018-08-09 |
| 20180221321 | METHODS AND PRODUCTS RELATED TO GLUTAMINASE INHIBITORS | 2018-08-09 |
| 20180221322 | OMEGA-3 FATTY ACID ARTICLES OF MANUFACTURE, AND METHODS AND APPARATUS FOR MAKING SAME | 2018-08-09 |
| 20180221323 | Treatment and Prevention of Liver Disease Associated with Parenteral Nutrition (PN) | 2018-08-09 |
| 20180221324 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS | 2018-08-09 |
| 20180221325 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS | 2018-08-09 |
| 20180221326 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS | 2018-08-09 |
| 20180221327 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS | 2018-08-09 |
| 20180221328 | Treatment of Obesity Using Non-Daily Administration of 6-O-(4-Dimethylaminoethoxy) Cinnamoyl Fumagillol | 2018-08-09 |
| 20180221329 | CIS- AND TRANS-SUFFRUTICOSOL D AS THERAPEUTIC AGENTS | 2018-08-09 |
| 20180221330 | MODULATORS OF MITOCHONDRIAL PROTEIN IMPORT | 2018-08-09 |
| 20180221331 | PREVENTION OF ROSACEA INFLAMMATION | 2018-08-09 |
| 20180221332 | Flash-Melt Cannabinoid Formulations | 2018-08-09 |
| 20180221333 | OPTIMIZED CANNABIS-BASED APHRODISIAC AND MOOD ENHANCER | 2018-08-09 |
| 20180221334 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | 2018-08-09 |
| 20180221335 | LASOFOXIFENE TREATMENT OF BREAST CANCER | 2018-08-09 |
| 20180221336 | DOSE SPARING KETOROLAC FORMULATIONS AND METHODS AND DEVICES FOR USE WITH SAME | 2018-08-09 |
| 20180221337 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | 2018-08-09 |
| 20180221338 | Topical Compositions Comprising Fipronil and Permethrin and Methods of Use | 2018-08-09 |
| 20180221339 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | 2018-08-09 |
| 20180221340 | METHODS AND COMPOSITIONS FOR DAILY OPHTHALMIC ADMINISTRATION OF PHENTOLAMINE TO IMPROVE VISUAL PERFORMANCE | 2018-08-09 |
| 20180221341 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | 2018-08-09 |
| 20180221342 | HEPATITIS C VIRUS INHIBITORS | 2018-08-09 |
| 20180221343 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MACULAR DEGENERATION | 2018-08-09 |
| 20180221344 | CYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | 2018-08-09 |
| 20180221345 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | 2018-08-09 |
| 20180221346 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | 2018-08-09 |
| 20180221347 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | 2018-08-09 |
| 20180221348 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | 2018-08-09 |
| 20180221349 | THERAPEUTIC USE OF LEVOROTATORY SS-LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS | 2018-08-09 |
| 20180221350 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | 2018-08-09 |
| 20180221351 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | 2018-08-09 |
| 20180221352 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | 2018-08-09 |
| 20180221353 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | 2018-08-09 |
| 20180221354 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | 2018-08-09 |
| 20180221355 | USE OF GABOXADOL IN THE TREATMENT OF TINNITUS | 2018-08-09 |
| 20180221356 | METHOD OF WOUND HEALING | 2018-08-09 |
| 20180221357 | METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES | 2018-08-09 |
| 20180221358 | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT | 2018-08-09 |
| 20180221359 | ADMINISTRATION OF ETHYL 3-[(2-{[4-(HEXYLOXYCARBONYL-AMINOIMINOMETHYL)PHENYL-AMINO]METHYL}-1-METHY- L-1H-BENZIMIDAZOL-5-CARBONYL)PYRIDIN-2-YLAMINO]PROPIONATE | 2018-08-09 |
| 20180221360 | DOSE-DUMPING RESISTANT CONTROLLED RELEASE DOSAGE FORM | 2018-08-09 |
| 20180221361 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | 2018-08-09 |
| 20180221362 | EZH2 INHIBITORS AND MODULATION OF REGULATORY T-CELL FUNCTION | 2018-08-09 |
| 20180221363 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2018-08-09 |
| 20180221364 | METALLOENZYME INHIBITOR COMPOUNDS | 2018-08-09 |
| 20180221365 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | 2018-08-09 |
| 20180221366 | METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES | 2018-08-09 |
| 20180221367 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | 2018-08-09 |
| 20180221368 | SUBSTITUTED BENZOXAZEPINE FOR CANCER THERAPY | 2018-08-09 |
| 20180221369 | COMPOSITIONS AND METHODS FOR TREATING FIBROSING DISORDERS AND CANCER | 2018-08-09 |
| 20180221370 | COMBINATION THERAPY | 2018-08-09 |
| 20180221371 | TREATMENT FOR THE FETUS WITH CONGENITAL HEART DISEASE | 2018-08-09 |
| 20180221372 | VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION | 2018-08-09 |
| 20180221373 | METHOD OF TREATING INSOMNIA | 2018-08-09 |
| 20180221374 | DEUTERATED BARICITINIB | 2018-08-09 |
